| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f244c6155c2c1d73694b62b1c889927 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 |
| filingDate |
2014-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47860024e3154733f96f9e258433d5b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0183d468d2eaa22167c391ef41092f86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d85f3e3093d349d774e2def9d03940f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25541c3e5277fab372e117d08622bd30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44f990129638ba5bb1201643820b7630
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2886f89b8f78e51ef72bad459bae9e7c |
| publicationDate |
2015-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015283101-A1 |
| titleOfInvention |
Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers |
| abstract |
Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018132391-A1 |
| priorityDate |
2009-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |